Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients

Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Be...

Descripción completa

Detalles Bibliográficos
Autores principales: Colapietro, Francesca, Angelotti, Giovanni, Masetti, Chiara, Shiffer, Dana, Pugliese, Nicola, De Nicola, Stella, Carella, Francesco, Desai, Antonio, Ormas, Monica, Calatroni, Marta, Omodei, Paolo, Ciccarelli, Michele, Aliberti, Stefano, Reggiani, Francesco, Bartoletti, Michele, Cecconi, Maurizio, Lleo, Ana, Aghemo, Alessio, Voza, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457973/
https://www.ncbi.nlm.nih.gov/pubmed/37632080
http://dx.doi.org/10.3390/v15081738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457973/
https://www.ncbi.nlm.nih.gov/pubmed/37632080
http://dx.doi.org/10.3390/v15081738

Ejemplares similares